Disease Info Card

Pyotraumatic Dermatitis

Information about Pyotraumatic Dermatitis: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Pyotraumatic Dermatitis

Most recent studies have shown that Pyotraumatic Dermatitis shares some biological mechanisms with adenocarcinoma, bone-neoplasms, carcinogenesis, carcinoma, cell-transformation-neoplastic, colorectal-cancer, leukemia, lung-neoplasms, lymphatic-metastasis, malignant-neoplasm-of-breast, malignant-neoplasm-of-lung, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-squamous-cell-neoplasm, mammary-neoplasms, neoplasm-metastasis, neoplasms, pathologic-neovascularization, prostatic-neoplasms, tumor-angiogenesis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Pyotraumatic Dermatitis, and have been seen in publications frequently: Aging, Angiogenesis, Cell Cycle, Cell Growth, Cell Proliferation, Dna Methylation, Dna Repair, Dna Replication, Drug Resistance, Exocytosis, Gene Conversion, Immune Response, Localization, Meiosis, Methylation, Mismatch Repair, Pathogenesis, Translation, Transport, Transposition

Quite a number of genes have been found to play important roles in Pyotraumatic Dermatitis, such as APC, CD34, CDKN2A, CTLA4, DMD, ENG, HBA1, HLA-DQA1, HRAS, KLK3, MVD, NOD2, NR1I2, PAH, PECAM1, SARS2, TP53, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.